Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s stock price reached a new 52-week high during trading on Friday . The stock traded as high as $47.40 and last traded at $46.93, with a volume of 49561 shares changing hands. The stock had previously closed at $44.30.
Analysts Set New Price Targets
A number of research firms recently issued reports on MTSR. Wells Fargo & Company began coverage on shares of Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Guggenheim increased their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $55.00.
Check Out Our Latest Report on Metsera
Metsera Trading Down 3.6%
The stock has a 50-day moving average of $30.49.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Metsera
Several institutional investors and hedge funds have recently made changes to their positions in the company. Exchange Traded Concepts LLC bought a new stake in shares of Metsera in the 2nd quarter valued at about $1,153,000. Goldman Sachs Group Inc. bought a new stake in shares of Metsera in the 1st quarter valued at about $568,000. Rhumbline Advisers bought a new stake in shares of Metsera in the 1st quarter valued at about $520,000. Strs Ohio bought a new stake in shares of Metsera in the 1st quarter valued at about $76,000. Finally, Siren L.L.C. bought a new stake in shares of Metsera in the 1st quarter valued at about $4,083,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
